Tamer Hellou

Hematology
4301 W Markham St # 508
Little Rock, AR 72205

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Chromosome 1q Gain Defines a Plasma Cell-Dominant Adverse-Risk Subtype in AL Amyloidosis With Inferior Long-Term Survival.

Journal: American journal of hematology
Published: May 30, 2026

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of Exposure.

Journal: Research square
Published: April 17, 2026

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia.

Journal: American journal of hematology
Published: March 31, 2026

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Journal: American journal of hematology
Published: March 17, 2026

Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis.

Determinants of gastrointestinal disease burden and survival in systemic AL amyloidosis.

Journal: Blood advances
Published: January 14, 2026

Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL Amyloidosis.

Determinants of Gastrointestinal Disease Burden and Survival in Systemic AL Amyloidosis.

Journal: Blood advances
Published: January 14, 2026

Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo Clinic.

Primary Breast MALT Lymphoma: Clinical Features and Outcomes From a Single-Institution Experience at Mayo Clinic.

Journal: American journal of hematology
Published: September 25, 2025

Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.

Impact of t(11;14) primary cytogenetic abnormality and the cumulative effect of multiple high-risk cytogenetics at diagnosis on the outcomes of patients with primary plasma cell leukemia.

Journal: Blood cancer journal
Published: September 04, 2025

Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes.

Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes.

Journal: Blood cancer journal
Published: May 26, 2025

T cell redirecting therapy for relapsed multiple myeloma.

T cell redirecting therapy for relapsed multiple myeloma.

Journal: Discover oncology
Published: January 20, 2025

Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients.

Past use of metformin is associated with increased risk of myelodysplastic syndrome development in diabetes mellitus patients: a cross-sectional study of 54,869 patients.

Journal: BMC pharmacology & toxicology
Published: December 14, 2024

Low Alanine-Aminotransferase Blood Activity Is Associated with Increased Mortality in Chronic Lymphocytic Leukemia Patients: A Retrospective Cohort Study of 716 Patients.

Low Alanine-Aminotransferase Blood Activity Is Associated with Increased Mortality in Chronic Lymphocytic Leukemia Patients: A Retrospective Cohort Study of 716 Patients.

Journal: Cancers
Published: August 10, 2023
Showing 1-12 of 15

Last Updated: 09/26/2026